10-Q: Personalis Reports Q2 2025 Revenue Decline, Widened Loss

Personalis, Inc. reported a 24% decrease in second-quarter 2025 revenue and a widened net loss, driven by a significant decline in enterprise sales from a major customer, despite growth in clinical diagnostic and population sequencing segments.

Summary

• Revenue for Q2 2025 decreased by 24% to $17.2 million compared to $22.6 million in Q2 2024.
• Net loss for Q2 2025 widened to $20.1 million, or $0.23 per share, from $12.8 million, or $0.24 per share, in Q2 2024.
• For the six months ended June 30, 2025, total revenue decreased by 10% to $37.8 million from $42.1 million in the prior year period.
• Net loss for the six months ended June 30, 2025, was $35.8 million, compared to $25.8 million for the same period in 2024.
• Enterprise sales revenue, primarily from Natera, decreased by 71% in Q2 2025 and 70% for the six months ended June 30, 2025, compared to the same periods in 2024, as the company does not expect a long-term commercial relationship with Natera beyond 2025.
• Clinical diagnostic revenue increased by 301% in Q2 2025 and 149% for the six months ended June 30, 2025, driven by increased NeXT Dx test volume and NeXT Personal Dx reimbursements from certain private payors.
• Population sequencing revenue increased by 158% in Q2 2025 and 171% for the six months ended June 30, 2025, due to increased sample processing for the VA MVP.
• Cash and cash equivalents, and short-term investments totaled $173.2 million as of June 30, 2025, down from $185.0 million at December 31, 2024.

Sentiment

Score: 4

Explanation: The company continues to incur significant losses and experienced a notable revenue decline due to the expected termination of a major customer relationship (Natera). While there are positive developments in clinical adoption and expanded partnerships for new indications, the overall financial performance remains challenging, and the company continues to burn cash, necessitating potential future capital raises. The invalidation of two patents is also a negative.

Positives

• Clinical diagnostic revenue saw significant growth, increasing by 301% in Q2 2025 to $0.47 million and 149% for the six months ended June 30, 2025, to $0.78 million.
• Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025, indicating accelerating physician adoption of the NeXT Personal platform.
• Expanded strategic collaboration with Tempus AI, Inc. to include colorectal cancer as a new indication for the exclusive commercialization agreement for NeXT Personal Dx, extending the agreement term through November 25, 2029.
• Presented pivotal data at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting from the PREDICT and SCANDARE studies, demonstrating NeXT Personal's ability to predict therapy response in breast cancer, with nearly half of all positive detections found in the ultra-sensitive range.
• Additional data presented at ASCO from the Phase 3 CALLA trial in partnership with AstraZeneca showed NeXT Personal detected cervical cancer progression up to 16 months earlier than standard imaging.
• Population sequencing revenue increased by 158% in Q2 2025 to $3.31 million and 171% for the six months ended June 30, 2025, to $7.52 million, due to increased sample processing for the VA MVP.
• Net cash used in operating activities slightly decreased to $30.9 million for the six months ended June 30, 2025, from $31.2 million in the prior year period.

Negatives

• Total revenue decreased by 24% in Q2 2025 and 10% for the six months ended June 30, 2025, compared to the same periods in 2024.
• Net loss widened to $20.1 million in Q2 2025 and $35.8 million for the six months ended June 30, 2025, compared to $12.8 million and $25.8 million respectively in the prior year periods.
• Enterprise sales revenue, primarily from Natera, significantly decreased by 71% in Q2 2025 to $2.32 million and 70% for the six months ended June 30, 2025, to $4.78 million.
• The company does not expect to continue a long-term commercial relationship with Natera beyond 2025, which accounted for 38% of total revenue for the six months ended June 30, 2024.
• Cash and cash equivalents, and short-term investments decreased by $11.8 million from $185.0 million at December 31, 2024, to $173.2 million at June 30, 2025.
• Working capital decreased by $10.3 million from $171.9 million at December 31, 2024, to $161.6 million at June 30, 2025.
• Cost of revenue decreased at a lesser rate as compared to the corresponding revenue decrease in Q2 2025, primarily due to lower fixed overhead absorption and increased clinical diagnostic test costs where reimbursement rates were less than the cost to produce the tests.
• Two of the company's patents were recently challenged and subsequently invalidated during inter partes reviews initiated by Foresight Diagnostics Inc.

Risks

• The company has a history of losses and expects to incur significant losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
• Inability to increase sales of current services or successfully develop and commercialize other services/products, or gain sufficient market acceptance/reimbursement, could prevent profitability.
• Substantial customer concentration, with a limited number of customers (Moderna, VA MVP, Natera) accounting for a significant portion of revenue and accounts receivable, poses a risk if these relationships are reduced or terminated.
• The company does not expect a long-term commercial relationship with Natera beyond 2025, which could materially harm revenue, cash position, and results of operations.
• Building the clinical laboratory business is subject to reimbursement challenges, and the company may not establish medical necessity or adequate reimbursement rates (e.g., no Medicare coverage reimbursement for NeXT Personal Dx yet).
• Reliance on a limited number of suppliers, or in some cases, a sole supplier (Illumina), for laboratory instruments and materials, poses supply chain risks and potential interruptions.
• The company operates from a single facility in Fremont, California, making it vulnerable to natural disasters or operational disruptions.
• Risk of not being able to develop services and products to keep pace with rapid advances in technology, medicine, and science, leading to obsolescence.
• Personalized cancer therapies represent new therapeutic approaches, potentially leading to heightened regulatory scrutiny, delays in clinical development, or delays/inability to achieve regulatory approval, commercialization, or payor coverage.
• Loss of key members of the executive management team or inability to hire, retain, or motivate highly skilled personnel could adversely affect the business.
• Inability to manage future growth effectively could strain organizational, administrative, and operational infrastructure.
• Potential acquisitions, joint ventures, or investments could harm operating results, dilute ownership, or cause debt/expense.
• Tests may be subject to regulatory action if they do not comply with FDA or foreign regulatory requirements (e.g., IVDR in EEA), leading to substantial costs and delays.
• Internal information technology systems or those of third-party vendors may fail or suffer security breaches, leading to regulatory investigations, litigation, fines, and business disruptions.
• Failure or perceived failure to comply with stringent and evolving data privacy and security laws (HIPAA, HITECH, CCPA, GDPR) could lead to regulatory actions, litigation, and reputational harm.
• Employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards, which could cause significant liability and harm reputation.
• Changes in health care policy (e.g., ACA, IRA 2022, PAMA, OBBBA) could increase costs, decrease revenue, and impact sales and reimbursement for tests.
• Litigation or other proceedings related to intellectual property infringement, misappropriation, or other violations may require significant time and money, and could prevent test sales or impact stock price.
• Inability to license rights to necessary technologies on reasonable terms could prevent commercialization of new services/products.
• Inability to obtain, maintain, and enforce patent protection for products, services, or technologies, or if the scope is not broad enough, could allow competitors to develop similar offerings.
• Inability to protect the confidentiality of trade secrets and know-how could harm the business and competitive position.
• Use of open source software could subject proprietary software to general release, adversely affect sales, and lead to litigation.
• Inability to adequately protect trademarks and trade names could hinder name recognition in markets of interest.
• Inability to raise additional capital on acceptable terms in the future may limit the ability to continue to operate and expand operations.
• The market price of common stock may be volatile or decline steeply/suddenly regardless of operating performance, potentially leading to loss of investment.
• Quarterly results may fluctuate significantly due to factors like customer sample delivery timing, adversely impacting common stock value.
• Unstable market, economic, and geopolitical conditions (e.g., Russia-Ukraine war, Israel-Hamas conflict) may have serious adverse consequences on business, financial condition, and stock price.
• Adverse developments affecting the financial services industry (e.g., bank failures) could adversely affect current and projected business operations and financial condition.
• Concentration of cash at financial institutions in balances exceeding federally insured limits poses a risk of loss if institutions fail.
• Insiders or holders of greater than five percent of outstanding common stock may exercise significant control over the company and influence corporate matters.
• Future sales of shares by existing stockholders, or the perception that such sales could occur, could cause the stock price to decline.
• The company does not currently intend to pay dividends on common stock, so investment return depends on stock appreciation.
• Future sales and issuances of common stock or rights to purchase common stock, including under equity incentive plans and the at-the-market facility, could result in additional dilution.
• If securities or industry analysts do not publish research or reports about the business, or publish inaccurate or unfavorable research, the stock price and trading volume could decline.
• Delaware law and provisions in the amended and restated certificate of incorporation and bylaws could make a merger, tender offer, or proxy contest difficult, thereby depressing the trading price of common stock.
• The company's ability to use net operating losses to offset future taxable income may be subject to limitations due to ownership changes.
• Changes in tax laws or regulations (e.g., Tax Cuts and Jobs Act, CARES Act, IRA 2022, OBBBA) could adversely affect business and financial condition.
• The effective tax rate may fluctuate, and the company may incur obligations in tax jurisdictions in excess of accrued amounts.
• The exit of the U.K. from the EU (Brexit) could lead to further regulatory divergence and require additional expenses for product development, manufacturing, and commercialization.
• Environmental, social, and corporate governance (ESG) matters or reporting of such matters could negatively impact the business or stock price.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Failure to maintain effective internal control over financial reporting in the future could adversely affect the accuracy and timing of financial reporting.

Future Outlook

The company expects to incur significant losses for the foreseeable future and may not achieve or sustain profitability. Research and development, as well as selling, general and administrative expenses, are anticipated to increase to support the growth of clinical diagnostic offerings. Revenue from Natera is expected to be lower in 2025, with no long-term commercial relationship anticipated beyond this year. Spending on raw materials and laboratory supplies is projected to increase in 2025 to support planned increases in clinical test volumes, ahead of expected Medicare reimbursement. Capital expenditures are expected to increase to approximately $7.0 million in 2025 and between $13.0 million to $14.0 million in each of 2026 and 2027, primarily for expanding NeXT Personal Dx capacity. Current cash, cash equivalents, and short-term investments are deemed sufficient for near-term capital and operating needs for at least the next 12 months, but the company may seek additional equity or debt financing if needed.

Management Comments

• Delivered 3,478 clinical tests in the second quarter of 2025, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal platform.
• Broadened the strategic collaboration with Tempus to add colorectal cancer, a major new indication, to the exclusive commercialization agreement, positioning Personalis to win in this attractive market.
• Presented pivotal data at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, including results from the PREDICT and SCANDARE studies showing NeXT Personal's ability to predict therapy response in breast cancer. Notably, nearly half of all positive detections were found in the ultra-sensitive range.
• Additional data presented at ASCO from the Phase 3 CALLA trial in partnership with AstraZeneca showed NeXT Personal detected cervical cancer progression up to 16 months earlier than standard imaging.

Industry Context

The company operates in the highly competitive and rapidly evolving cancer genomics and precision oncology sector. The increasing focus on personalized cancer therapies and molecularly targeted oncology treatments drives demand for advanced diagnostic tools. The industry faces challenges in securing adequate reimbursement for novel diagnostic tests and navigating complex regulatory landscapes. Strategic partnerships, such as those with Tempus and Moderna, are crucial for market penetration and clinical validation in this capital-intensive field. The trend of major partners like Natera internalizing services highlights the competitive pressures and the need for companies to diversify their customer base and offerings.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable company results to directly assess financial performance against.
• The company states its capacity to sequence and analyze over 350 trillion bases of DNA per week and having sequenced approximately 500,000 human samples (200,000 whole human genomes), which it believes is 'larger than most cancer genomics companies.' This is a self-assessment, not a direct comparison to specific industry standards or competitors' published capacities.
• Clinical utility data presented at ASCO (PREDICT, SCANDARE, CALLA trials) demonstrates progress in validating NeXT Personal's capabilities, which is crucial for market acceptance in the oncology diagnostics space. However, without specific comparative trial data from competitors, a direct assessment against industry-wide clinical utility benchmarks is not possible from the filing.

Corporate Governance

Legal Proceedings

• As of June 30, 2025, the company was not involved in any material legal proceedings.
• Past litigation with Foresight Diagnostics Inc. for patent infringement was settled in June 2024, resulting in the dismissal of complaints.
• Two of the company's patents were challenged and subsequently invalidated during inter partes reviews initiated by Foresight Diagnostics Inc.

Related Party Transactions

• Tempus AI, Inc. (Tempus) is a related party due to owning more than 10% of common stock.
• The company has a Commercialization and Reference Laboratory Agreement with Tempus, under which Tempus markets NeXT Personal Dx in the U.S. and the company compensates Tempus on a per-test basis.
• As of June 30, 2025, the company received $5.0 million of a $6.0 million Market Development Fee from Tempus.
• Tempus exercised warrants in August 2024 for $18.4 million cash and purchased an additional 3.5 million shares for $17.7 million cash under an investment agreement.
• Related party sales and marketing expenses to Tempus were $0.9 million for Q2 2025 and $1.5 million for the six months ended June 30, 2025.
• Unamortized Market Development Fees from Tempus were $2.8 million (current) and $1.1 million (long-term) as of June 30, 2025.
• Accrued payable to Tempus was $0.9 million as of June 30, 2025.
• Merck & Co., Inc. (Merck) is a related party due to owning more than 10% of common stock.
• In December 2024, Merck purchased 14,044,943 shares of common stock at $3.56 per share for $50.0 million cash under an investment agreement.
• The company agreed to reserve $10.0 million of proceeds from the Merck investment to open an ISO-certified laboratory outside the U.S.
• The company has a Master Service Agreement with Merck since June 2017, amended in February 2024 to include clinical laboratory services.
• Invoiced $1.9 million (Q2 2025) and $2.4 million (six months ended June 30, 2025) from Merck.
• Related party accounts receivable from Merck were $1.9 million as of June 30, 2025.

Stakeholder Impact

• Shareholders face dilution from ongoing At-the-Market (ATM) facility sales and past investment agreements (Tempus, Merck). Continued net losses and cash burn negatively impact shareholder value, and the stock price is subject to volatility. No dividends are expected in the foreseeable future.
• Employees have been impacted by workforce reductions in 2023 (nearly 50% of workforce). The company relies on highly skilled personnel and faces intense competition for talent, with stock-based compensation being a significant component of their remuneration.
• Customers, particularly pharmaceutical companies, experience variability in revenue due to the timing of clinical trials. The significant decline in enterprise sales from Natera, and the expectation of no long-term relationship beyond 2025, will materially impact revenue. Clinical diagnostic customers benefit from new test offerings and expanded indications.
• Suppliers, especially sole-source providers like Illumina, are critical to the company's operations, and any disruptions could impact the company's ability to conduct business.
• Creditors are exposed to the company's financial health, as it continues to incur losses and relies on capital raises to fund operations and meet outstanding loan and lease liabilities.

Next Steps

• Continue to invest resources in product development and sales and marketing efforts.
• Further increase sales to existing customer groups and expand the customer base.
• Develop a growing set of state-of-the-art services and products.
• Advance operational infrastructure and build regulatory credentials.
• Focus marketing efforts on large pharmaceutical companies.
• Build and publish clinical evidence-base for products and services in key indications.
• Pursue reimbursement coverage from Medicare and other payors for clinical diagnostic offerings.
• Seek additional partnerships.
• Expand NeXT Personal Dx capacity, with capital expenditures expected to be approximately $7.0 million in 2025 and between $13.0 million to $14.0 million in each of 2026 and 2027.
• Actively market the vacated Menlo Park space for sublease.
• Evaluate the impact of adopting new accounting guidance (ASU 2023-09 and ASU 2024-03).
• Open an ISO-certified laboratory in a region outside the United States, mutually agreed upon with Merck, using $10.0 million of proceeds from the Merck investment.

Key Dates

Recommendation

While Personalis, Inc. shows promising advancements in clinical adoption and strategic partnerships, particularly with Tempus AI for new cancer indications and positive clinical trial data, its financial performance remains a significant concern. The substantial decline in revenue, primarily due to the expected cessation of the Natera relationship, coupled with widening net losses and continued cash burn, indicates ongoing operational challenges. The company's reliance on a few major customers and the recent invalidation of two patents add to the risk profile. The recent capital raises provide some liquidity, but the need for future funding remains. For a seasoned investor, the current situation presents a mixed bag: strong scientific and clinical progress against a backdrop of deteriorating financials. A 'Hold' recommendation allows investors to monitor the company's ability to offset the Natera revenue loss with growth in other segments and achieve better cost control, while acknowledging the inherent risks and the need for further capital.

Keywords

Cancer genomics, Precision oncology, Personalized cancer therapies, Genomic tests, Liquid biopsy, NeXT Personal Dx, NeXT Dx, Molecular residual disease (MRD), Whole exome sequencing (WES), Whole genome sequencing (WGS), Pharmaceutical, Clinical trials, Biomarker discovery, Tempus AI, ModernaTX, Natera, Merck, VA Million Veteran Program, ASCO, FDA, CLIA, CAP, Intellectual property, Biotechnology, Healthcare, Diagnostics